LPL Financial LLC increased its holdings in AstraZeneca plc (NYSE:AZN) by 5.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,921 shares of the company’s stock after purchasing an additional 5,709 shares during the period. LPL Financial LLC’s holdings in AstraZeneca were worth $4,661,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in AZN. FMR LLC boosted its stake in AstraZeneca by 0.8% in the 1st quarter. FMR LLC now owns 56,832,723 shares of the company’s stock worth $2,297,746,000 after buying an additional 458,752 shares during the last quarter. Primecap Management Co. CA boosted its position in shares of AstraZeneca by 0.3% in the first quarter. Primecap Management Co. CA now owns 56,343,156 shares of the company’s stock worth $2,277,954,000 after acquiring an additional 195,230 shares during the last quarter. Fisher Asset Management LLC boosted its position in shares of AstraZeneca by 3.4% in the second quarter. Fisher Asset Management LLC now owns 15,904,291 shares of the company’s stock worth $656,529,000 after acquiring an additional 529,694 shares during the last quarter. GQG Partners LLC boosted its position in shares of AstraZeneca by 72.0% in the first quarter. GQG Partners LLC now owns 5,155,269 shares of the company’s stock worth $207,823,000 after acquiring an additional 2,157,252 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its holdings in AstraZeneca by 141.3% in the first quarter. OppenheimerFunds Inc. now owns 4,105,290 shares of the company’s stock valued at $165,977,000 after purchasing an additional 2,403,920 shares during the period. Hedge funds and other institutional investors own 17.68% of the company’s stock.
AZN has been the subject of several research analyst reports. ValuEngine lowered shares of AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Argus lifted their price target on shares of AstraZeneca to $50.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Finally, DZ Bank cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Tuesday, September 3rd. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $45.96.
AZN traded down $0.26 on Wednesday, reaching $43.01. 3,118,140 shares of the company’s stock were exchanged, compared to its average volume of 2,645,863. AstraZeneca plc has a twelve month low of $35.30 and a twelve month high of $45.69. The company’s 50 day moving average is $44.26 and its 200-day moving average is $41.15. The company has a debt-to-equity ratio of 1.19, a quick ratio of 0.75 and a current ratio of 0.95. The company has a market cap of $113.01 billion, a price-to-earnings ratio of 24.86, a PEG ratio of 1.45 and a beta of 0.49.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, July 25th. The company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.30 by $0.43. The business had revenue of $5.72 billion for the quarter, compared to the consensus estimate of $5.57 billion. AstraZeneca had a net margin of 9.38% and a return on equity of 35.83%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.69 EPS. Sell-side analysts forecast that AstraZeneca plc will post 1.81 EPS for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Rule of 72
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.